Form 4: Entera Bio Director, Yonatan Malca, Receives Stock Options and Shares in Lieu of Fees

Director Yonatan Malca receives stock options and shares from Entera Bio in lieu of cash fees and as an annual grant.

Summary

• Yonatan Malca, a director of Entera Bio Ltd., received 8,216 ordinary shares on January 15, 2025, in lieu of cash fees for services rendered as a director for the fourth quarter of 2024.
• Malca also received 28,509 stock options on January 15, 2025, as part of the Board's annual grant to directors, exercisable at $2.28 per share and expiring on January 15, 2035.
• The stock options vest ratably on a quarterly basis over a one-year period starting January 1, 2025.
• Following these transactions, Malca directly owns 47,259 ordinary shares and 28,509 stock options.

Sentiment

Score: 6

Explanation: Neutral sentiment as it reflects standard compensation practices. The receipt of shares in lieu of cash could be seen as a positive sign of the director's commitment.

Positives

• The receipt of shares in lieu of cash fees could be seen as a positive sign of the director's commitment to the company's long-term success.
• The grant of stock options aligns the director's interests with those of the shareholders.

Industry Context

This filing is a routine disclosure related to director compensation and equity ownership, common in publicly traded companies.

Comparison to Industry Standards

• Director compensation packages often include a mix of cash and equity.
• Granting stock options that vest over time is a standard practice to incentivize long-term performance.
• The vesting schedule of the options (quarterly over one year) is fairly typical.

Stakeholder Impact

• Shareholders may view the equity-based compensation as aligning director interests with company performance.
• Employees may see this as a standard practice for director compensation.

Key Dates